Prior to joining Arialys Therapeutics, Mathew (he/him) directed corporate development and strategic partnerships at a number of San Diego-based organizations, including Cidara Therapeutics, BD Biosciences, and Scripps Research. While at Scripps Research, he led the invention disclosure review for more than $40 million annually in industry-sponsored basic research annually over three years ,while also participating in 1-2 new company formation events per year, including Epic Sciences, Abide Therapeutics, and Receptos. He has partnered at nearly every stage of drug development, representing more than $1.7 billion in transaction value, with companies as diverse as Novartis, Janssen, Pfizer, Mundipharma, LEO pharma, Ventana, Biotechne, and DAKO. Mathew received a M.S. in chemistry from UC San Diego and a B.S. in biochemistry from UC Davis.